18 Multiple Myeloma Clinical Trials in Ann Arbor, MI (2026)

Q: How do I join a clinical trial in Ann Arbor?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Ann Arbor research site will contact you.

Recruiting Multiple Myeloma Studies in Ann Arbor

NCT02735707Recruiting

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to impro...

Ann Arbor, MIPHASE320,000 participantsUMC Utrecht

View Study Details

NCT00246857Recruiting

Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death

This study will determine the biochemical and genetic causes of inherited immune diseases affecting lymphocyte homeostasis. Lymphocytes are a type of white blood cell that fights infections. Normally,...

Ann Arbor, MI5,000 participantsNational Institute of Allergy and Infectious Diseases (NIAID)

View Study Details

NCT04634552Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3)....

Ann Arbor, MIPHASE2510 participantsJanssen Research & Development, LLC

View Study Details

NCT05438043Recruiting

A Study of Daratumumab

The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research a...

Ann Arbor, MIPHASE3500 participantsJanssen Research & Development, LLC

View Study Details

NCT06351631Recruiting

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bome...

Ann Arbor, MIPHASE3400 participantsMerck Sharp & Dohme LLC

View Study Details

NCT03761108Recruiting

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs ...

Ann Arbor, MIPHASE1387 participantsRegeneron Pharmaceuticals

View Study Details

NCT04643002Recruiting

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the contr...

Ann Arbor, MIPHASE1258 participantsSanofi

View Study Details

NCT07210580Recruiting

Testing the Impact of Measurement-Based Care on Quality of Life and Disease Management Among Veterans With Inflammatory Bowel Disease

This research study is addressing issues related to Inflammatory bowel disease (IBD), which is a chronic autoimmune disorder that affects over 60,000 Veterans. With close monitoring and timely treatme...

Ann Arbor, MINA250 participantsVA Office of Research and Development

View Study Details

NCT06106945Recruiting

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and prelimina...

Ann Arbor, MIPHASE1226 participantsAstraZeneca

View Study Details

NCT06920004Recruiting

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo re...

Ann Arbor, MIPHASE3218 participantsargenx

View Study Details

NCT06953960Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity o...

Ann Arbor, MIPHASE1199 participantsAbbVie

View Study Details

NCT06140524Recruiting

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

This study is researching an investigational drug called linvoseltamab ("study drug") in participants at moderate risk of developing multiple myeloma (about 3 to 10% average annual risk), a group that...

Ann Arbor, MIPHASE2116 participantsRegeneron Pharmaceuticals

View Study Details

NCT06680037Recruiting

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel)....

Ann Arbor, MIPHASE1100 participantsTG Therapeutics, Inc.

View Study Details

NCT07219043Recruiting

A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation

In this study, researchers will learn more about a drug called felzartamab in people who have received a kidney transplant and later developed a condition called microvascular inflammation (MVI). MVI ...

Ann Arbor, MIPHASE281 participantsBiogen

View Study Details

NCT06057402Recruiting

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab...

Ann Arbor, MIPHASE480 participantsPfizer

View Study Details

NCT07007962Recruiting

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

This is a multinational, open label, single arm study that will evaluate the impact of early multi-immune modulation with rilzabrutinib in adult ITP patients who failed first-line treatment. The study...

Ann Arbor, MIPHASE360 participantsSanofi

View Study Details

NCT06401356Recruiting

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionall...

Ann Arbor, MIPHASE350 participantsNovartis Pharmaceuticals

View Study Details

NCT06188793Recruiting

Virtual Reality (VR) -Directed Brain Gut Behavioral Treatment (BGBT) for Inflammatory Bowel Disease (IBD) Inpatients

The research is studying virtual reality (VR)-directed brain-gut behavioral therapy (BGBT) as a pain treatment option for hospitalized patients with inflammatory bowel disease (IBD). This study is bei...

Ann Arbor, MINA40 participantsUniversity of Michigan

View Study Details

About Multiple Myeloma Clinical Trials in Ann Arbor

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 18 multiple myeloma clinical trials recruiting participants in Ann Arbor, MI. These studies are seeking a combined 28,475 participants. Research is being sponsored by UMC Utrecht, National Institute of Allergy and Infectious Diseases (NIAID), Janssen Research & Development, LLC and 12 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Ann Arbor — FAQ

Are there multiple myeloma clinical trials in Ann Arbor?

Yes, there are 18 multiple myeloma clinical trials currently recruiting in Ann Arbor, MI. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Ann Arbor?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Ann Arbor research site will contact you about next steps.

Are clinical trials in Ann Arbor free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Ann Arbor studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 18 active trials in Ann Arbor are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated July 17, 2026 from ClinicalTrials.gov